Our portfolio company Sirius Medical secures growth funding from new and existing investors to further develop the Sirius Pintuition portfolio and expand international sales
Eindhoven, 4th of February 2025 – Our portfolio company Sirius Medical, a leading medtech company and market leader in oncological surgical marker navigation, has raised €10 million in funding on World Cancer Day. This investment round was led by Invest-NL and Nextgen Ventures, with support from De Groot Family Office and existing investors Brabant Development Agency (BOM), Holland Capital, Curie Capital, Team Holmium, and Sirius Medical’s team.
World Cancer Day is a poignant reminder of the ongoing fight against cancer, and this milestone reflects Sirius Medical’s commitment to enhancing cancer care. Praised by breast cancer surgeons worldwide, the Sirius Pintuition® surgical navigation platform enables simple, best-in-class wire-free localization for breast-conserving surgery in any hospital. This latest funding round empowers Sirius Medical to enhance the Sirius Pintuition system and GPSDetect™ software platform, focusing on usability and intuitiveness, and extending its applications. Additionally, the investment will substantially bolster the sales infrastructure and support expansion into new markets.
“Announcing this funding milestone on World Cancer Day underscores the urgency of our mission to improve cancer care globally,” says Bram Schermers, CEO of Sirius Medical. “This funding round, in the current fundraising environment, is a clear testament to the talent of the Sirius Medical team, and the Pintuition technology that we have developed. We are proud to continue contributing to the fight against cancer and look forward to the next phase of growth for Sirius Medical. We will have more exciting news to announce soon.”
“From Holland Capital, we have been supporting Sirius Medical for many years to bridge the notorious ‘valley of death,’” said Jan Frens van Giessel, partner at Holland Capital. “Many young companies in medical technology fail due to a lack of funding, as reported by Financieele Dagblad a few weeks ago. For investors, investing in medical technology is risky because the development and sales processes are complex, uncertain, and lengthy. We experience this at Holland Capital as well, but when a company manages to distinguish itself and achieves key technical and commercial milestones, we do everything we can to arrange financing. This is also the case with Sirius Medical.”
“We have seen Sirius Medical grow over the years into a successful med-tech scale-up, with sales in the US, UK, almost all EU countries, and Australia. We are proud of the impressive results the Sirius Medical team has achieved. We welcome the new investors, NextGen and InvestNL, so that together we can make this Dutch healthcare innovation available to women with breast cancer worldwide,” said Jan Frens van Giessel, partner at Holland Capital.
About World Cancer Day
World Cancer Day, observed on February 4th, is a global initiative to raise awareness, inspire action, and work together to reduce the impact of cancer worldwide.
About Sirius Medical
With its roots in the Netherlands Cancer Institute, Sirius Medical is dedicated to improving care for cancer patients by delivery of unsurpassed, yet affordable solutions that enable precise and efficient removal of tumors. Sirius Pintuition is precise, simple, affordable and both CE marked, and FDA cleared. Sirius Medical is rapidly expanding with over 250 centers and 35.000 procedures globally.
Holland Capital invests in the growth ambitions of Adjust
Holland Capital invests in the growth ambitions of Adjust Amsterdam/Amstelveen, January 23rd , 2024 – Holland Capital invests in Adjust, a renowned procurement and contract management advisory firm serving the public, semi-public, and private sectors. Holland...
Holland Capital investeert in de groeiambities van Adjust
Holland Capital investeert in de groeiambities van Adjust Amsterdam/ Amstelveen, 23 januari 2024 - Holland Capital investeert in Adjust, een gerenommeerd inkoop- en contractmanagement adviesbureau voor de publieke, semipublieke en private sector. De investering van...
Emixa kondigt rebranding van gelieerde bedrijven aan
Emixa kondigt rebranding van gelieerde bedrijven aan Naarden, 8 januari 2024 - Ons portfoliobedrijf Emixa, de toonaangevende partner voor digitale transformatie, kondigt de rebranding aan van zijn gelieerde bedrijven onder de Emixa merknaam in de Benelux en het VK. De...
Emixa Announces Rebranding of Affiliated Companies
Emixa Announces Rebranding of Affiliated Companies Naarden, January 8, 2024 – Our portfolio company Emixa, the leading Digital Transformation partner, announces the rebranding of its affiliated companies under the Emixa brand name in the Benelux and UK region....
Holland Capital kijkt terug op een succesvol 2023
Holland Capital kijkt terug op een succesvol 2023 Amsterdam/Düsseldorf, 22 december 2023 – Met een heldere investeringsstrategie blijft Holland Capital actief in de aantrekkelijke groeimarkten Technology, Healthcare en Agrifood. In 2023 hebben wij onze...
Holland Capital invests in Data platform for medical research
Holland Capital invests in Data platform for medical research Amsterdam/Düsseldorf, 19 December 2023 – Holland Capital invests in German company Honic for further development of their medical data platform. Using this funding, Honic is able to further roll out its...
Amsterdam
Krijn Taconiskade 426
1087 HW Amsterdam
+31 (0) 20 3119411
Düsseldorf
Königsallee 42
40212 Düsseldorf
+49 (0) 211 96290120
Contact
info@hollandcapital.nl



